Anitocabtagene Autoleucel

Summary

Anitocabtagene Autoleucel (CHEMBL5314723) is a phase-3 clinical-stage gene; indicated across 2 conditions including plasma cell myeloma and neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Gene
• Indications: 2 conditions
• Clinical trials: 2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5314723
Name	Anitocabtagene Autoleucel
Type	Gene
Max phase	3

Also known as: Anitocabtagen autoleucel, Anitocabtagene autoleucel, CART-ddBCMA, ANITOCABTAGENE AUTOLEUCEL

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
plasma cell myeloma	3	MONDO:0009693	EFO:0001378
neoplasm	1	MONDO:0005070	EFO:0000616

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06413498	PHASE3	RECRUITING	A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
NCT07045909	PHASE2	RECRUITING	Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).